Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S-Reference-Cited by-同舟云学术

Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S

Published:2022-03-03 Issue:9 Volume:386 Page:847-860
ISSN:0028-4793
Container-title:New England Journal of Medicine
language:en
Short-container-title:N Engl J Med

Author:

Sadoff Jerald¹,Gray Glenda¹^ORCID,Vandebosch An¹,Cárdenas Vicky¹,Shukarev Georgi¹,Grinsztejn Beatriz¹,Goepfert Paul A.¹,Truyers Carla¹,Van Dromme Ilse¹,Spiessens Bart¹,Vingerhoets Johan¹,Custers Jerome¹,Scheper Gert¹,Robb Merlin L.¹,Treanor John¹,Ryser Martin F.¹,Barouch Dan H.¹,Swann Edith¹,Marovich Mary A.¹,Neuzil Kathleen M.¹,Corey Lawrence¹^ORCID,Stoddard Jeffrey¹,Hardt Karin¹,Ruiz-Guiñazú Javier¹,Le Gars Mathieu¹,Schuitemaker Hanneke¹^ORCID,Van Hoof Johan¹,Struyf Frank¹^ORCID,Douoguih Macaya¹

Affiliation:

1. From Janssen Vaccines and Prevention, Leiden, the Netherlands (J. Sadoff, G. Shukarev, J.C., G. Scheper, M.L.G., H.S., J.V.H., M.D.); the South African Research Council, Cape Town, South Africa (G.G.); Janssen Research and Development, Beerse, Belgium (A.V., C.T., I.V.D., B.S., J.V., M.F.R., K.H., J.R.-G., F.S.); Janssen Research and Development, Spring House, PA (V.C.); Evandro Chagas National Institute of Infectious Diseases–Fiocruz, Rio de Janeiro (B.G.); the University of Alabama at Birmingham,...

Funder

NIAID to the HIV Vaccine Trials Network (HVTN) Leadership and Operations Center

NIAID to the HVTN Statistics and Data Management Center

NIAID to the HVTN Laboratory Center

NIAID to the HIV Prevention Trials Network (HPTN) Leadership and Operations Center

NIAID to the AIDS Clinical Trials Group (ACTG) Leadership and Operations Center

NIAID to the Infectious Diseases Clinical Research Consortium Leadership Group

NIAID to the Vaccine and Therapeutic Evaluation Units

Janssen Research and Development, an affiliate of Janssen Vaccines and Prevention and part of the Janssen pharmaceutical companies of Johnson & Johnson

Publisher

Massachusetts Medical Society

Subject

General Medicine

Link

http://www.nejm.org/doi/pdf/10.1056/NEJMoa2117608

Reference19 articles.

1. Ad26 vector-based COVID-19 vaccine encoding a prefusion-stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses

2. Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine

3. Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19

4. Statistics in Clinical Vaccine Trials

5. Durable Humoral and Cellular Immune Responses 8 Months after Ad26.COV2.S Vaccination

Cited by 163 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Revisiting the dimensions of universal vaccine with special focus on COVID-19: Efficacy versus methods of designing;International Journal of Biological Macromolecules;2024-10

2. Hybrid immunity augments cross-variant protection against COVID-19 among immunocompromised individuals;Journal of Infection;2024-10

3. Emerging and reemerging infectious diseases: global trends and new strategies for their prevention and control;Signal Transduction and Targeted Therapy;2024-09-11

4. Impact of High Covid-19 Vaccination Rate in an Aging Population: Estimating Averted Hospitalizations and Deaths in the Basque Country, Spain Using Counterfactual Modeling;Journal of Epidemiology and Global Health;2024-08-26

5. Beyond COVID-19: the promise of next-generation coronavirus vaccines;npj Viruses;2024-08-22